aTyr Pharma, Inc.(US:ATYR) Globenewswireยท2025-10-28 00:18Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4] Group 3: Case Allegations - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage completely, leading to investor damages when the truth was revealed [5]